Because the recruitment of neutrophils to sites of inflammation involves CXCR2, a high-affinity receptor for IL-8, CXCR2 antagonists have been developed and tested as an add-on to standard therapy in patients with persistent uncontrolled asthma. The gene discussed is CXCR2; the disease is asthma.